FDA committee backs Roche’s lymphoma treatment

The Swiss pharmaceutical company said Friday that the oncologic drugs advisory committee had voted 11 to two in favor of Polivy in combination with Rituxan plus cyclophosphamide, doxorubicin and prednisone to treat the disease, though the move isn't binding.